OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.
OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leading researchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.
With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021.
Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.
Global Kinetics Corporation Limited develops mobile health technology for the management of patients with Parkinson’s disease and other movement disorders. The company focuses on developing technology for the monitoring, quantification, and reporting of movement symptoms of neurological diseases. It offers PKG Data Logger, a wrist worn device that automatically records movement data to assist doctors in their diagnosis and treatment of the symptoms of movement disorders, such as Parkinson’s disease. The company was founded in 2007 and is based in Melbourne, Australia.
QUE Oncology, Inc. engages in drug development and therapies for treatment of cancer, such as breast cancer and prostate cancer. The company licenses intellectual property in the areas of scientific research. The company was founded in 2013 and is based in Atlanta, Georgia.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIRO and is headquartered in Melbourne, Australia. MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015.
Elastagen Pty Ltd., a clinical stage medical company, produces and sells products based on the human protein tropoelastin. The company offers injectable dermoaesthetic products, stretch mark products, scar revision and wound healing products, and sealant and osteoskeletal products for applications areas, including skin rejuvenation, scar remodeling, and tissue repair. It sells its products through online orders. Elastagen Pty Ltd. was founded in 2003 and is based in Eveleigh, Australia with production operations in Europe; and clinical operations in the United Kingdom. As of April 6, 2018, Elastagen Pty Ltd. operates as a subsidiary of Allergan plc.
Cardiora Pty Ltd. is a clinical stage biopharmaceutical company based in Melbourne, Australia, founded in 2015. The company focuses on developing innovative treatments for patients suffering from end-stage heart failure, a condition characterized by high mortality rates and frequent hospital admissions. Cardiora's lead product, CRD-102, is an oral medication specifically designed for this patient population. As of now, the company is conducting Phase Ib trials and completing IND enabling studies, with plans to advance into Phase II trials. Through its research and development efforts, Cardiora aims to improve the quality of life for individuals facing this serious health challenge.
MetaBloQ Pty Ltd is a biotechnology company based in Melbourne, Australia, specializing in the development of innovative drugs aimed at treating challenging cancers, including triple-negative breast cancer, prostate cancer, and melanoma. Founded in 2016, the company focuses on discovering and developing therapies that target specific metabolic processes within cancer cells, with the goal of minimizing toxicity to non-cancerous cells. Through its research and development efforts, MetaBloQ aims to provide patients with safer and more effective treatment options, enhancing their overall quality of life during cancer therapy.
Aravax Pty Ltd. is a biotechnology company based in Melbourne, Australia, specializing in developing treatments for peanut allergies. Founded in 2014, the company aims to create the first safe and effective treatment that helps patients tolerate peanuts without triggering allergic reactions. Utilizing proprietary technology, Aravax focuses on resetting the immune system to achieve this tolerance. The company emerged through the acquisition of intellectual property developed by Alfred Health and Monash University, positioning itself at the forefront of innovative solutions for peanut allergy management.
Global Kinetics Corporation Limited develops mobile health technology for the management of patients with Parkinson’s disease and other movement disorders. The company focuses on developing technology for the monitoring, quantification, and reporting of movement symptoms of neurological diseases. It offers PKG Data Logger, a wrist worn device that automatically records movement data to assist doctors in their diagnosis and treatment of the symptoms of movement disorders, such as Parkinson’s disease. The company was founded in 2007 and is based in Melbourne, Australia.
OccuRx Pty. Ltd., a biopharmaceutical company, engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. It has a library of chemical compounds with potent anti-inflammatory and anti-fibrotic properties to treat diabetic retinopathy and other fibrotic diseases of the retina. The company was incorporated in 2013 and is based in Melbourne, Australia.
Solvanix Pty Ltd., a biotechnology company, provides technology for improving stability and reducing the aggregation of fully human antibodies. It provides StAbilize, which works by boosting stability and reducing aggregation of monoclonal antibodies, antibody fragments, and bi-specifics. The company works with biotech and pharma industries developing therapeutic antibodies by providing human binding domain sequences. It also provides commercial licenses and non-exclusive licenses. The company was incorporated in 2014 and is headquartered in Darlinghurst, Australia.
Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Protego Medical Pty Ltd is a medical technology company based in Melbourne, Australia, founded in 2013. The company specializes in developing a device designed to provide sternal protection during cardiac surgery, aiming to enhance patient safety and surgical outcomes.
PolyActiva Pty Ltd develops therapeutic products for the clinical treatment of ocular diseases and other applications. It uses a drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films, and fibers. It offers latanoprost ocular implants for the treatment of glaucoma; levofloxacin ocular implants for prevention of endophthalmitis following ocular surgery; and anti-inflammatory programs. PolyActiva Pty Ltd was founded in 2009 and is based in Melbourne, Australia with laboratory location in Parkville, Australia.
Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.
G I Therapies develops an innovative non-invasive medical device for the treatment of chronic constipation (CC) in adults and children. GI Therapies was established in Melbourne in 2012 to commercialise innovative technology the treat gastrointestinal motility disorders including chronic constipation, irritable bowel syndrome with constipation and gastroparesis.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.
Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.
Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.
Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.